GlassScriptPhysician profile
Kiwon Park
NPI 1346124864
$911.06
in general payments reported to CMS, 2019-2025
23 companies · $911 in 2025
The $911 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878 · Education: $32.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.34 |
| Education | $32.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $87.58 | 2025 | Jakafi, Monjuvi, Zynyz |
| Pfizer INC. | $85.89 | 2025 | |
| Janssen Biotech, INC. | $84.14 | 2025 | Talvey, Darzalex, Rybrevant |
| Merck Sharp & Dohme LLC | $66.68 | 2025 | Keytruda Qlex, Keytruda, Welireg |
| Puma Biotechnology, INC. | $60.21 | 2025 | |
| Daiichi Sankyo INC. | $55.00 | 2025 | Datroway, Enhertu |
| Eisai INC. | $49.60 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.21 | 2025 | Iclusig |
| Astrazeneca Pharmaceuticals LP | $34.72 | 2025 | Imfinzi |
| Amgen INC. | $32.72 | 2025 | |
| Aveo Pharmaceuticals, INC. | $31.80 | 2025 | |
| Beone Medicines USA, INC. | $31.43 | 2025 | Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $28.69 | 2025 | |
| Glaxosmithkline, LLC. | $27.00 | 2025 | Blenrep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.35 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.29 | 2025 | |
| Coherus Oncology, INC. | $23.05 | 2025 | Loqtorzi |
| Sobi, INC | $21.53 | 2025 | |
| Shorla Oncology INC. | $21.18 | 2025 | |
| Kyowa Kirin, INC. | $20.33 | 2025 | |
| Taiho Oncology, INC. | $18.65 | 2025 | |
| Recordati_rare_diseases_inc. | $18.42 | 2025 | Enjaymo |
| Tersera Therapeutics LLC | $16.59 | 2025 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiwon Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.